Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

SRTM vs NIVF: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

SRTM Captures Overall Composite Edge (47.6 HOLD vs 47.7 HOLD), While NIVF Leads 3–1 on Growth & Valuation Pillars

SRTM Overall Winner 6-Pillar Tally: SRTM 1 – 3 NIVF (2 Tie) Matrix Metrics: SRTM 2 – 5 NIVF

As of Nov 20, 2026, SRTM (SRTM) captures the overall head-to-head institutional edge over NewGenIvf Group Limited Class A (NIVF) on higher Unified Composite conviction (47.6/100 HOLD vs. 47.7/100 HOLD) after splitting the core matrix 2–5 (led by Options & Positioning), while NIVF wins 3–1 across the 6-pillar growth and valuation breakdown. SRTM trades at $0.08 (N/M Forward P/E, N/A operating margin) versus NIVF at $0.03 (N/M Forward P/E, -238.2% operating margin).

  • Growth vs. Quality Trade-Off: SRTM earns the overall head-to-head edge with a stronger Unified Composite Score (47.6/100 HOLD vs. NIVF 47.7/100 HOLD) and N/A risk profile, whereas NIVF leads top-line expansion (-4.7% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: SRTM trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI N/A); meanwhile NIVF is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 32.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About SRTM vs NIVF
SRTM US Equity Head-to-Head Winner
SRTM
Institutional Equity
$0.08
-14.59% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol N/A
Unified Composite Score
47.6 / 100 HOLD
Tech 50.0 Fund 50.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Trend telemetry aligned with daily close.
RSI-14: N/A · SMA20: N/A · SMA50: N/A
NIVF NASDAQ
NewGenIvf Group Limited Class A ordinary shares
Services-Misc Health & Allied Services, Nec
$0.03
-23.14% 1D
Market Cap $98,000
TTM Revenue $4.6M
Forward P/E N/M
Beta / 30D Vol 0.05β · 3040% Vol
Unified Composite Score
47.7 / 100 HOLD
Tech 43.0 Fund 49.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -15.9%), weak momentum, RSI 33
RSI-14: 32.9 · SMA20: $0.56 · SMA50: $0.46

6-Pillar Scorecard Institutional Category Breakdown (SRTM 1 – 3 NIVF)

Columns: Metric · SRTM · NIVF
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale NIVF
Revenue Growth (YoY) N/A -4.7%
Earnings Growth (YoY) N/A +0.0%
TTM Revenue (USD) N/A $4.6M
Market Cap N/A $98,000
3. Profitability & Quality NIVF
Gross Margin N/A 23.9%
Operating Margin N/A -238.2%
Net Profit Margin N/A 24.2%
Return on Equity (ROE) N/A 5.5%
4. Balance Sheet & Cash Flow NIVF
Cash Generation (TTM) N/A -$11M EBITDA
Cash Flow Margin N/A N/A
Net Cash / Leverage N/A ROE $733.75 Book/Sh · 5.5% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning SRTM
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Institutional Equity Operator Medical Care Facilities Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: SRTM (2) vs NIVF (5)
Institutional Metric SRTM NIVF Criterion Row Edge
Market Capitalization
Scale
N/A $98,000 Larger Scale NIVF
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
N/A -4.7% Higher Growth NIVF
Operating Margin (TTM)
Profitability
N/A -238.2% Higher Margin NIVF
Net Profit Margin
Profitability
N/A 24.2% Higher Margin NIVF
Return on Equity (ROE)
Capital Efficiency
N/A 5.5% Higher ROE NIVF
52-Week Range Position
Momentum
2% ($0–$1) 0% ($0–$3) Stronger Trend SRTM
Beta / 30D Volatility
Risk Regime
N/A 0.05β · 3040% Vol Lower Realized Risk SRTM
Unified Institutional Score
Composite Signal
47.6 / 100 (HOLD) 47.7 / 100 (HOLD) Higher Composite Tie
Trailing 12M Revenue (USD)
Operating Scale
N/A $4.6M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 23.9% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE) -$11M EBITDA ($733.75 Book/Sh · 5.5% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon SRTM +1.53 pp
SRTM: -80.4% · NIVF: -81.93%
3M Horizon SRTM +3.67 pp
SRTM: -86.83% · NIVF: -90.5%
6M Horizon SRTM +3.67 pp
SRTM: -86.83% · NIVF: -90.5%
1Y Horizon SRTM +3.67 pp
SRTM: -86.83% · NIVF: -90.5%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on SRTM vs NIVF. Trailing 12-month operating profitability (SRTM N/A vs NIVF -238.2%) and valuation multiples (SRTM N/M vs NIVF N/M Forward P/E) are benchmarked directly in Pillar 4 below.

SRTM ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M
NIVF ADR TTM Benchmark FX-Normalized USD
TTM Revenue$4.6M
Gross Margin23.9%
Op. Margin-238.2%
ROE / Fwd P/E5.5% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
SRTM UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact SRTM Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
NIVF BREAKDOWN
19d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact NIVF Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
SRTM Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
NIVF Moat Profile Cyclical / Execution-Driven Positioning
Medical Care Facilities Operator
Competes within the Medical Care Facilities value chain with $98,000 market capitalization and -238.2% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ SRTM vs NIVF Key Questions & Quantitative Answers

As of Nov 20, 2026, SRTM (SRTM) captures the overall head-to-head institutional edge over NewGenIvf Group Limited Class A (NIVF) on higher Unified Composite conviction (47.6/100 HOLD vs. 47.7/100 HOLD) after splitting the core matrix 2–5 (led by Options & Positioning), while NIVF wins 3–1 across the 6-pillar growth and valuation breakdown. SRTM trades at $0.08 (N/M Forward P/E, N/A operating margin) versus NIVF at $0.03 (N/M Forward P/E, -238.2% operating margin). Growth vs. Quality Trade-Off: SRTM earns the overall head-to-head edge with a stronger Unified Composite Score (47.6/100 HOLD vs. NIVF 47.7/100 HOLD) and N/A risk profile, whereas NIVF leads top-line expansion (-4.7% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: SRTM trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI N/A); meanwhile NIVF is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 32.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

NIVF leads the Growth & Scale pillar: SRTM posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with NIVF at -4.7% YoY revenue growth and +0.0% YoY earnings growth on $4.6M TTM revenue (23.9% gross margin, -238.2% operating margin). On trailing 12-month operating scale, SRTM generates N/A in USD-normalized revenue versus $4.6M for NIVF. In operating R&D and SG&A reinvestment, SRTM deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for NIVF.

SRTM and NIVF trade at balanced relative valuation multiples. SRTM trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas NIVF trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SRTM (N/A ROE) versus NIVF (5.5% ROE) capital efficiency.

In options market volatility and institutional positioning, SRTM carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (N/A realized risk). By comparison, NIVF carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (0.05β · 3040% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.